LALPATHLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2019-04-01 2020-03-31 2020-05-07 INR Millions Yearly Single segment the business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2020-01-01 2020-03-31 Audited Consolidated 3017000000.00 120000000.00 3137000000.00 720000000.00 0.00 0.00 625000000.00 39000000.00 200000000.00 1099000000.00 2683000000.00 454000000.00 0.00 454000000.00 159000000.00 -31000000.00 128000000.00 0.00 326000000.00 0.00 0.00 0.00 0.00 326000000.00 -22000000.00 304000000.00 325000000.00 1000000.00 303000000.00 1000000.00 833000000.00 10 3.94 3.93 0.00 0.00 3.94 3.93 0.00 0.00 0.00 i.tThe above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 18 May, 2020 respectively. The consolidated financial results for the year ended 31 March, 2020 have been audited and for the quarter ended 31 March, 2020 have been reviewed by the statutory auditors of the Company and they have expressed an unmodified opinion thereon. nii.tThe above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). niii.tThese financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. niv.tFigures for the quarter ended 31 March, 2020 and 31 March, 2019 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2019 and 31 December, 2018 respectively, which was subjected to limited review. nv.tDuring the year ended 31 March, 2020, the Parent Company has issued 3,267 equity shares of face value of INR 10 each on exercise of employee stock options. nvi.tEffective 1 April, 2019, Ind AS 116 Leases” has been adopted by the Group using the modified retrospective transition method. Accordingly, the comparatives for earlier periods presented have not been restated. This has resulted in recognising right of use of assets amounting to INR 1,477 million and lease liabilities amounting to INR 1,320 million. Consequently on transition to Ind AS 116, profit before tax for the current quarter and year ended 31 March 2020 is lower by INR 22 million and 95 million respectively. nvii.tDuring the year ended 31 March, 2020, a new wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited has been incorporated in Kenya. The Parent Company has subscribed to equity share capital amounting to INR 7 million in the subsidiary. nviii.tDuring the year ended 31 March, 2020, Pathlabs Unifiers Private Limited (a subsidiary) has purchased the businesses of “Bawankar Pathology”, M/s Shree Computerised Pathology Laboratory and Modern Diagnostics & Modern Lab engaged in the business of providing pathological diagnostics services in Bhandara, Yavatmal and Sangli respectively, on a going concern basis for a purchase consideration of INR 52 million, INR 41 million and INR 36 million respectively. nix.tAs approved in their meeting held on 7 August, 2019, during the quarter ended 30 September, 2019, the Board of Directors of Pathlabs Unifiers Private Limited (a subsidiary), acquired an equity stake of 70% in Centrapath Labs Private Limited engaged in pathology business for a consideration of INR 469 million. nx.tAs approved in their meeting held on 13 November, 2019, during the quarter ended 31 December, 2019, the Board of Directors of Pathlabs Unifiers Private Limited (a subsidiary), acquired an equity stake of 70% in APRL Pathlabs Private Limited engaged in pathology business for a consideration of INR 53 million. n nDue to size constraint Note no. 11, 12, 13, 14 & 15 cannot be given here, for complete notes please refer PDF file for Financial Results – 31.03.2020. Single segment 2019-04-01 2020-03-31 Audited Consolidated 13304000000.00 550000000.00 13854000000.00 2987000000.00 0.00 0.00 2426000000.00 153000000.00 728000000.00 4455000000.00 10749000000.00 3105000000.00 0.00 3105000000.00 838000000.00 -9000000.00 829000000.00 0.00 2276000000.00 0.00 0.00 0.00 0.00 2276000000.00 -11000000.00 2265000000.00 2259000000.00 17000000.00 2248000000.00 17000000.00 833000000.00 10 0.00 27.42 27.37 0.00 0.00 27.42 27.37 0.00 0.00 0.00 Fees to collection centers/channel partners 393000000.00 Other expenses 706000000.00 Fees to collection centers/channel partners 1730000000.00 Other expenses 2725000000.00